Highlights ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Real-time Estimate Cboe BZX Other stock markets 01:40:42 2024-04-30 pm EDT			5-day change	1st Jan Change
1.275 ^USD	-8.93%		-5.93%	+9.48%

Apr. 10	ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	CI
Mar. 26	ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	Apr. 10	CI
ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	Mar. 26	CI
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
ABVC BioPharma Signs Licensing Deal With Senior Paradise	Feb. 15	MT
ABVC BioPharma, Inc. Executes a Definitive Agreement to Receive License Fees of $3 Million and Royalties of 2% on Future Revenue	Feb. 15	CI
ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study	Dec. 07	CI
ABVC BioPharma, Inc. Enters Definitive Agreement with Licensing Income Worth $467 Million and Royalties Up to $200 Million	Nov. 16	CI
Earnings Flash (ABVC) ABVC BIOPHARMA Reports Q3 Revenue $15,884	Nov. 15	MT
ABVC BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
ABVC BioPharma Enters Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million	23-10-26	CI
Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study	23-10-17	CI
ABVC BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
ABVC BioPharma, Inc. Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration	23-08-03	CI
ABVC BioPharma, Inc. Announces the Signing of A Legally Binding Term Sheet with Xinnovation Therapeutics Co., Ltd	23-08-01	CI
ABVC BioPharma to Acquire Stake in Chinese Real Estate For Strategic Investments	23-07-26	MT
ABVC BioPharma Sets 1-for-10 Reverse Stock Split	23-07-24	MT
ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia	23-05-22	CI
ABVC BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
ABVC BioPharma, Inc. Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center	23-04-10	CI
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Highlights

Filters